India's Piramal Pharma up after FDA closes inspection of US unit
** Shares of Piramal Pharma PIRM.NS up as much as 4.2% to
120.4 rupees
** Stock on track for a fourth consecutive session of gains,
if trend holds
** Pharmaceuticals firm said the US Food and Drug
Administration (US FDA) has issued an Establishment Inspection
Report (EIR) for its manufacturing facility at Bethlehem in the
US, after closing an inspection
** Stock last up 3.9%, boosting YTD gains to 7.3%
(Reporting by Navamya Ganesh Acharya in Bengaluru)
((Navamya.GaneshAcharya@thomsonreuters.com; +91 8805175330 ;))
Recent news on Piramal Pharma (Mumbai)
See all newsBrief: Piramal Pharma Receives Permanent Revocation Of Closure Order For Dahej Site
Brief: Piramal Pharma Solutions Announces Partnership With Botanix To Support Drug Substance Development
Brief: Piramal Pharma Announces Successful Closure Of Us FDA Inspection At Digwal Facility
India's Piramal Pharma eyes complex drug demand for earnings boost, chair says
Brief: Piramal Pharma Says Closure Of US FDA Inspection At Manufacturing Facility At Lexington